Type 1 Diabetes

Clearance given to initiate clinical trial for treatment for type 1 diabetes

Published in Medical Letter on the CDC and FDA, November 14th, 2004

Transition Therapeutics Inc. (TTH) has received clearance from the United States Food and Drug Administration (FDA) to initiate a clinical trial for its diabetes product, E1-I.N.T., in type 1 diabetes patients.

This clinical trial will be evaluating efficacy, safety, and tolerability of a 28-day course of daily E1-I.N.T. treatments with a 6-month follow-up. E1- I.N.T. is a short course combination therapy aimed at stimulating the regeneration of the body's insulin-producing cells.

This clinical study will be conducted in clinical centers in the United States. Transition plans to expand these trials into type 2 diabetes patients.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-11-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry